• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

MacKenzie Scott, Melinda French Gates, and Lauren Sánchez Bezos are rewriting the rules of billionaire giving—one quietly, one strategically, one very publicly

2

Summer camps remain a battleground over what it means to be American

3

Current price of oil as of July 13, 2026

1

MacKenzie Scott, Melinda French Gates, and Lauren Sánchez Bezos are rewriting the rules of billionaire giving—one quietly, one strategically, one very publicly

2

Summer camps remain a battleground over what it means to be American

3

Current price of oil as of July 13, 2026
HealthOzempic

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By
The Associated Press
The Associated Press
,
Kenya Hunter
Kenya Hunter
, and
Linley Sanders
Linley Sanders
Down Arrow Button Icon
By
The Associated Press
The Associated Press
,
Kenya Hunter
Kenya Hunter
, and
Linley Sanders
Linley Sanders
Down Arrow Button Icon
January 31, 2025, 2:26 PM ET
Ozempic and Wegovy medications side by side
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.Steve Christo-Corbis—Corbis via Getty Images
Add Fortune on Google for similar content.

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition tied to weight, but they are not broadly supportive of teens who have obesity using the medications, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.

Recommended Video

When it comes to ages 12 to 18 who are dealing with obesity, Americans are divided: About one-third say the use of weight-loss drugs in this context is a “very” or “somewhat” good thing, a similar share say it’s a bad thing and about 3 in 10 say it isn’t good or bad.

For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing.

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in popularity after the Food and Drug Administration approved them for weight loss in 2021. Now, they’re all over the place — celebrities, TV advertisements, social media, news media, your neighbor.

Doctors and researchers say the injectable drugs are a effective tools when it comes to treating obesity. The American Medical Association has urged health insurance companies to cover the drugs, and the American Academy of Pediatrics has said that doctors should consider giving the medications to kids 12 and older who are struggling with obesity.

The AP-NORC poll results indicate that even as doctors urge the drugs’ use, some Americans continue to have concerns about weight-loss drugs, particularly for teens and people who aren’t struggling with obesity.

How many Americans are obese?

According to the Centers for Disease Control and Prevention, more than 100 million adults in the U.S. are obese — defined as having a body mass index of 30 or higher — and more than 22 million adults are severely obese, with a BMI of 40 or higher.

Obesity is classified as a chronic disease that needs medical attention, because it can result from genetics, environmental factors and socioeconomic factors. Patients who use the drugs as an extra boost to lose weight can face criticism that they’re somehow “cheating,” said Dr. Cate Varney, who treats patients with obesity at UVA Health in Charlottesville, Virginia.

“It’s like telling somebody to nail a nail into a board and then giving one person a hammer and another person, you know, like a chopstick,” Varney said, adding, “we’re leveling the playing field with these medications.”

Anjanette Ewen lost 67 pounds on Mounjaro, and credits that weight loss as the reason she found a cancerous lump on her breast. The 50-year-old from Fort Walton Beach, Florida, who responded to the AP-NORC poll, said she had struggled to lose weight for years because of complications with polycystic ovarian syndrome.

Because of PCOS, which has a common symptom of sudden weight fluctuations, Ewen went from 150 pounds to 220 pounds in eight months.

“I’ve been on a weight loss journey for forever, it seems like, and nothing was working,” she said.

About 20% of children in the U.S. have obesity, according to CDC data. Dr. Gitanjali Srivastava, the medical director of obesity medicine at Vanderbilt University School of Medicine, said obesity is easier to treat in children than in adults.

“The youth actually respond beautifully to these medications,” she said, adding that obesity at a young age increases the chance “of having even severe and more profound obesity as an adult … to the point that you will actually have to have medications and or bariatric surgery as an adult.”

How much does Ozempic cost without insurance?

Without insurance, out-of-pocket costs for the drugs can run hundreds of dollars each time you fill a prescription.

The AP-NORC poll shows about half of Americans “strongly” or “somewhat” favor having the federal programs Medicare and Medicaid cover weight-loss drugs for people who have obesity, while about 2 in 10 are opposed the idea and about one-quarter have a neutral view.

So far, Medicare, the health insurance program for 66 million Americans 65 and older, doesn’t cover the drugs for obesity. Coverage varies under Medicaid, which provides health insurance for low-income Americans.

Some large companies with 500 employees or more and some Medicaid programs are adding coverage. But many other employers and health insurers are scaling back, with some citing treatment costs.

Can you use Ozempic if you’re not obese?

You can’t get weight-loss drugs without a prescription, though there are off-market compounds that people can purchase.

The AP-NORC poll showed that about 6 in 10 Americans believe it is a “very” or “somewhat” bad thing for adults to take GLP-1s for weight loss if they’re not obese, and that increases to about 7 in 10 for teens in the same situation.

Younger adults, though, are a little more open to the use of GLP-1s for teens who aren’t dealing with obesity. About 8 in 10 Americans above the age of 45 believe it’s a “bad idea” for teenagers who want to lose weight by using the drugs but aren’t obese, but about two-thirds of American adults under the age of 45 hold the same opinion.

___

AP Health Writer Tom Murphy in Indianapolis contributed to this report. Hunter reported from Atlanta. Sanders reported from Washington.

___

The AP-NORC poll of 1,147 adults was conducted Jan. 9-13, using a sample drawn from NORC’s probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 3.9 percentage points.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

The Fortune 500 Innovation Forum will convene Fortune 500 executives, U.S. policy officials, top founders, and thought leaders to help define what’s next for the American economy, Nov. 16-17 in Detroit. Apply here.
About the Authors
By The Associated Press
See full bioRight Arrow Button Icon
By Kenya Hunter
See full bioRight Arrow Button Icon
By Linley Sanders
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

A leadership consultant’s warning to managers: Don’t mistake grief for underperformance
Workplace CultureHuman resources
A leadership consultant’s warning to managers: Don’t mistake grief for underperformance
By Mikaela Cohen and HR BrewJuly 14, 2026
3 hours ago
aca
North AmericaHealth Insurance
2.6 million Americans dropped ACA coverage as subsidies expired — fraud or price shock?
By Aparna Soni and The ConversationJuly 14, 2026
4 hours ago
r
CommentaryFDA
Trust in the FDA is collapsing. It’s time to get really transparent about our food and our drugs
By Jeffrey Sonnenfeld, Megan Ranney, Sten Vermund, Patricia Greenstein and Steven TianJuly 14, 2026
4 hours ago
mm
North Americaaging
Washington gerontocracy meets its receipt-check moment: ‘I think we need some transparency’
By Jill Colvin and The Associated PressJuly 14, 2026
7 hours ago
Best Recumbent Bikes (2026): Athlete Approved
HealthDietary Supplements
Best Recumbent Bikes (2026): Athlete Approved
By Christina SnyderJuly 13, 2026
1 day ago
GOP Sen. Mitch McConnell ends frenzied speculation about his health, revealing a fall led to his hospitalization and he’s now in a rehab center
PoliticsU.S. Senate
GOP Sen. Mitch McConnell ends frenzied speculation about his health, revealing a fall led to his hospitalization and he’s now in a rehab center
By The Associated PressJuly 12, 2026
2 days ago

Most Popular

MacKenzie Scott, Melinda French Gates, and Lauren Sánchez Bezos are rewriting the rules of billionaire giving—one quietly, one strategically, one very publicly
Newsletters
MacKenzie Scott, Melinda French Gates, and Lauren Sánchez Bezos are rewriting the rules of billionaire giving—one quietly, one strategically, one very publicly
By Sydney LakeJuly 14, 2026
6 hours ago
Summer camps remain a battleground over what it means to be American
North America
Summer camps remain a battleground over what it means to be American
By Seth T. Kannarr, Derek H. Alderman and The ConversationJuly 13, 2026
1 day ago
Current price of oil as of July 13, 2026
Personal Finance
Current price of oil as of July 13, 2026
By Joseph HostetlerJuly 13, 2026
2 days ago
The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents
Innovation
The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents
By Sasha RogelbergJuly 12, 2026
2 days ago
Current price of silver as of Tuesday, July 14, 2026
Personal Finance
Current price of silver as of Tuesday, July 14, 2026
By Joseph HostetlerJuly 14, 2026
13 hours ago
Current price of gold as of July 13, 2026
Personal Finance
Current price of gold as of July 13, 2026
By Danny BakstJuly 13, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.